C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/12 (2006.01) A61K 38/17 (2006.01) C07K 14/71 (2006.01) C12N 5/16 (2006.01) C12P 21/00 (2006.01) A61K 38/00 (2006.01) A61K 48/00 (2006.01)
Patent
CA 2397705
The present invention discloses purified and isolated nucleic acid sequences encoding polypeptides having a structure substantially similar to that of splicing forms of mammalian GFR.alpha.4 comprising the amino acid sequence (SEQ ID NO:1:) - (SEQ ID NO:6:). The preferred sequences comprise cDNAs having the sequence (SEQ ID NO:7:) - (SEQ ID NO :13:). The present invention is also related to purified and isolated polypeptides comprising the amino acid sequence and or substantially similar splicing forms of mammalian GFRà4. Furthermore, the invention is related to substances capable of specifically recognizing said polypeptides and including both antibodies and receptors. The active compounds of the present invention including cDNAS, polypeptides, binding substances, and antibodies. The invention is useful not only for producing cell-lines and/or transgenic non-human animal but also for diagnosing and treating neuronal disorders or endocrine tumours as well as other related diseases by enabling measurements of GFR.alpha.4-mediated signalling in endocrine cells and neurons.
La présente invention concerne des séquences d'acide nucléique purifié et isolé codant des polypeptides qui possèdent une structure sensiblement similaire à celle des formes épissées du GFR.alpha.4 mammalien, qui comprennent la séquence d'acides aminés (SEQ ID NO:1:) - (SEQ ID NO:6:). Les séquences préférées comprennent des ADNc de séquence (SEQ ID NO:7:) - (SEQ ID NO:13:). L'invention concerne également des polypeptides purifiés et isolés comprenant la séquence d'acides aminés et/ou des formes épissées sensiblement similaires du GRF.alpha.4. En outre, l'invention concerne des substances capables de reconnaître spécifiquement les polypeptides précités, et comprenant tant des anticorps que des récepteurs. Les composés actifs de la présente invention comprennent des ADNc, des polypeptides, des substances de liaison et des anticorps. L'invention est utilisée non seulement pour produire des lignées cellulaires et/ou des animaux non humains transgéniques, mais également pour diagnostiquer et traiter des troubles neuraux ou des tumeurs endocrines ainsi que d'autres maladies liées, étant donné qu'elle permet de mesurer la signalisation dont le GFR.alpha.4 est médiateur dans les cellules endocrines et les neurones.
Airaksinen Matti
Lindahl Maria
Poteriaev Dimitri
Rossi Jari
Saarma Mart
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Licentia Ltd.
LandOfFree
Compounds related to or derived from gfr.alpha.4 and their use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds related to or derived from gfr.alpha.4 and their use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds related to or derived from gfr.alpha.4 and their use will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1402544